Marcus O Butler

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7104662/publications.pdf

Version: 2024-02-01

92	4,603	147566	118652
papers	citations	31 h-index	62 g-index

93	93	93	6162
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. Journal of Clinical Oncology, 2022, 40, 127-137.	0.8	446
2	KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. European Journal of Cancer, 2022, 160, 1-11.	1.3	4
3	Recommended first-line management of brain metastases from melanoma: A multicenter survey of clinical practice. Radiotherapy and Oncology, 2022, 168, 89-94.	0.3	4
4	Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma. MDM Policy and Practice, 2022, 7, 238146832210896.	0.5	5
5	Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. Frontiers in Oncology, 2022, 12, 818679.	1.3	8
6	Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. Journal of Clinical Oncology, 2022, 40, 1939-1948.	0.8	29
7	Turnaround Times in Melanoma BRAF Testing and the Impact on the Initiation of Systemic Therapy at a Single Tertiary Care Cancer Center. JCO Oncology Practice, 2022, , OP2100810.	1.4	1
8	CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus. Cancers, 2022, 14, 89.	1.7	5
9	The addition of fludarabine to cyclophosphamide for lymphodepleting chemotherapy enhances the persistence of infused NY-ESO-1 TCR anticancer therapy TBI-1301.. Journal of Clinical Oncology, 2022, 40, 2539-2539.	0.8	0
10	Customized autoantibodies (autoAbs) profiling to predict and monitor immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology, 2022, 40, 2528-2528.	0.8	3
11	Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab. , 2022, 10, e004378.		4
12	The effect of circadian rhythm on clinical outcome in patients receiving pembrolizumab in the INSPIRE pan-cancer trial.. Journal of Clinical Oncology, 2022, 40, 2589-2589.	0.8	2
13	Leveraging personalized circulating tumor DNA (ctDNA) for detection and monitoring of molecular residual disease in high-risk melanoma.. Journal of Clinical Oncology, 2022, 40, 9579-9579.	0.8	5
14	Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.. Journal of Clinical Oncology, 2022, 40, 9522-9522.	0.8	37
15	Study design of a global molecular disease characterization initiative (MDCI) in oncology clinical trials.. Journal of Clinical Oncology, 2022, 40, e13598-e13598.	0.8	0
16	Real-world changes in the clinical management of resected stage III melanoma at high risk of local recurrence in the era of modern systemic therapies.. Journal of Clinical Oncology, 2022, 40, e21575-e21575.	0.8	0
17	Safety and efficacy results from the expansion phase of the first-in-human study evaluating TGFÎ² inhibitor SAR439459 alone and combined with cemiplimab in adults with advanced solid tumors.. Journal of Clinical Oncology, 2022, 40, 2524-2524.	0.8	3
18	Development of a remote monitoring program for melanoma/skin oncology patients at Princess Margaret Cancer Centre.. Journal of Clinical Oncology, 2022, 40, e18630-e18630.	0.8	0

#	Article	IF	Citations
19	Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy. Nature Immunology, 2022, 23, 1273-1283.	7.0	17
20	Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy. , 2021, 9, e001642.		28
21	Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4+ T cells. Nature Biotechnology, 2021, 39, 958-967.	9.4	15
22	Defining the Criteria for Reflex Testing for BRAF Mutations in Cutaneous Melanoma Patients. Cancers, 2021, 13, 2282.	1.7	6
23	Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigatorâ€™s choice (IC) in first-line metastatic uveal melanoma.. Journal of Clinical Oncology, 2021, 39, 9527-9527.	0.8	8
24	Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events. Current Oncology, 2021, 28, 2173-2179.	0.9	14
25	Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors. Cancers, 2021, 13, 3640.	1.7	4
26	Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules. Clinical Cancer Research, 2021, 27, 5280-5288.	3.2	21
27	Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. Nature Communications, 2021, 12, 5137.	5.8	63
28	Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. New England Journal of Medicine, 2021, 385, 1196-1206.	13.9	376
29	Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target. Melanoma Research, 2021, 31, 27-37.	0.6	6
30	Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201). Clinical Cancer Research, 2020, 26, 804-811.	3.2	39
31	Development of the Functional Assessment of Cancer Therapyâ€“Immune Checkpoint Modulator (FACTâ€ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. Cancer, 2020, 126, 1550-1558.	2.0	26
32	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. Nature Communications, 2020, 11, 6262.	5.8	50
33	An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors. , 2020, 8, e000883.		36
34	Adjuvant nivolumab versus ipilimumab in resected stage IIIBâ€“C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 1465-1477.	5.1	330
35	Guillain-BarrÃ© Syndrome following a series of novel therapies adapting the gold-standard in the era of immune priming. Journal of Neuroimmunology, 2020, 346, 577267.	1.1	1
36	Cancer patientsâ€™ experiences with immune checkpoint modulators: A qualitative study. Cancer Medicine, 2020, 9, 3015-3022.	1.3	21

#	Article	IF	Citations
37	Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). Clinical Cancer Research, 2020, 26, 2477-2486.	3.2	16
38	Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy. Cancer Immunology Research, 2020, 8, 926-936.	1.6	73
39	Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma. ELife, 2020, 9, .	2.8	13
40	Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221. Clinical Cancer Research, 2019, 25, 6052-6060.	3.2	61
41	Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. JNCI Cancer Spectrum, 2019, 3, pkz071.	1.4	4
42	Validation of CyTOF Against Flow Cytometry for Immunological Studies and Monitoring of Human Cancer Clinical Trials. Frontiers in Oncology, 2019, 9, 415.	1.3	114
43	Chaperones of the class I peptide-loading complex facilitate the constitutive presentation of endogenous antigens on HLA-DP84GGPM87. Journal of Autoimmunity, 2019, 102, 114-125.	3.0	2
44	TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses. International Journal of Gynecological Cancer, 2019, 29, 346-352.	1.2	29
45	Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. Cancer Immunology, Immunotherapy, 2019, 68, 773-785.	2.0	94
46	Hyperprogressive disease in earlyâ€phase immunotherapy trials: Clinical predictors and association with immuneâ€related toxicities. Cancer, 2019, 125, 1341-1349.	2.0	115
47	GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment. Science Immunology, 2019, 4, .	5.6	85
48	Arginine methylation of FOXP3 is crucial for the suppressive function of regulatory T cells. Journal of Autoimmunity, 2019, 97, 10-21.	3.0	34
49	A novel chimeric antigen receptor containing a JAKâ€“STAT signaling domain mediates superior antitumor effects. Nature Medicine, 2018, 24, 352-359.	15.2	349
50	A Subset of Human Autoreactive CD1c-Restricted T Cells Preferentially Expresses TRBV4-1+ TCRs. Journal of Immunology, 2018, 200, 500-511.	0.4	17
51	Mechanisms underlying the lack of endogenous processing and CLIP-mediated binding of the invariant chain by HLA-DP84Gly. Scientific Reports, 2018, 8, 4804.	1.6	8
52	Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirusâ€“Related Cervical Carcinoma. JAMA Oncology, 2018, 4, e173776.	3.4	116
53	Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience. Melanoma Research, 2018, 28, 571-577.	0.6	25
54	Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. British Journal of Cancer, 2018, 119, 670-674.	2.9	114

#	Article	IF	Citations
55	DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models. Nature Communications, 2018, 9, 1915.	5.8	21
56	Malignant Bowel Obstruction in Advanced Gynecologic Cancers: An Updated Review from a Multidisciplinary Perspective. Obstetrics and Gynecology International, 2018, 2018, 1-10.	0.5	23
57	Response to Immune Checkpoint Inhibition in Two Patients with Alveolar Soft-Part Sarcoma. Cancer Immunology Research, 2018, 6, 1001-1007.	1.6	50
58	A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium. Clinical Cancer Research, 2018, 24, 6168-6174.	3.2	44
59	HLA-DP84Gly constitutively presents endogenous peptides generated by the class I antigen processing pathway. Nature Communications, 2017, 8, 15244.	5.8	28
60	Immune modulatorâ€induced changes in the gastrointestinal tract. Histopathology, 2017, 71, 494-496.	1.6	56
61	Key Residues at Third CDR3Î² Position Impact Structure and Antigen Recognition of Human Invariant NK TCRs. Journal of Immunology, 2017, 198, 1056-1065.	0.4	3
62	From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely. Clinical Cancer Research, 2017, 23, 4980-4991.	3.2	14
63	Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities. Clinical Cancer Research, 2017, 23, 4992-5002.	3.2	41
64	Transient stimulation expands superior antitumor T cells for adoptive therapy. JCI Insight, 2017, 2, e89580.	2.3	37
65	Mouse and Human CD1d-Self-Lipid Complexes Are Recognized Differently by Murine Invariant Natural Killer T Cell Receptors. PLoS ONE, 2016, 11, e0156114.	1.1	3
66	CD4+ and CD8+ TCRÎ² repertoires possess different potentials to generate extraordinarily high-avidity T cells. Scientific Reports, 2016, 6, 23821.	1.6	13
67	Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma. Oncology Letters, 2016, 11, 1581-1585.	0.8	34
68	Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients. British Journal of Cancer, 2016, 115, 1186-1192.	2.9	50
69	Generating De Novo Antigen-specific Human T Cell Receptors by Retroviral Transduction of Centric Hemichain. Journal of Visualized Experiments, 2016, , .	0.2	2
70	CDR3Î² sequence motifs regulate autoreactivity of human invariant NKT cell receptors. Journal of Autoimmunity, 2016, 68, 39-51.	3.0	12
71	BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. Journal of Clinical Investigation, 2016, 126, 3479-3494.	3.9	168
72	Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy. Cancer Immunology Research, 2015, 3, 1070-1081.	1.6	29

#	Article	IF	Citations
73	Specific Roles of Each TCR Hemichain in Generating Functional Chain-Centric TCR. Journal of Immunology, 2015, 194, 3487-3500.	0.4	35
74	Pembrolizumab. , 2015, 3, 36.		171
75	Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.. Journal of Clinical Oncology, 2015, 33, 3003-3003.	0.8	120
76	New treatments for metastatic melanoma. Cmaj, 2014, 186, 754-760.	0.9	9
77	Human cellâ€based artificial antigenâ€presenting cells for cancer immunotherapy. Immunological Reviews, 2014, 257, 191-209.	2.8	96
78	IL-21 Can Supplement Suboptimal Lck-Independent MAPK Activation in a STAT-3â€“Dependent Manner in Human CD8+ T Cells. Journal of Immunology, 2012, 188, 1609-1619.	0.4	10
79	Ex Vivo Expansion of Human CD8+ T Cells Using Autologous CD4+ T Cell Help. PLoS ONE, 2012, 7, e30229.	1.1	31
80	Establishment of Antitumor Memory in Humans Using in Vitroâ€“Educated CD8 ⁺ T Cells. Science Translational Medicine, 2011, 3, 80ra34.	5.8	94
81	Induction of HLA-DP4â€“Restricted Anti-Survivin Th1 and Th2 Responses Using an Artificial Antigen-Presenting Cell. Clinical Cancer Research, 2011, 17, 5392-5401.	3.2	24
82	A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles. International Immunology, 2010, 22, 863-873.	1.8	39
83	Dissociation of Its Opposing Immunologic Effects Is Critical for the Optimization of Antitumor CD8+ T-Cell Responses Induced by Interleukin 21. Clinical Cancer Research, 2008, 14, 6125-6136.	3.2	18
84	Long-Lived Antitumor CD8+ Lymphocytes for Adoptive Therapy Generated Using an Artificial Antigen-Presenting Cell. Clinical Cancer Research, 2007, 13, 1857-1867.	3.2	123
85	Identification of an immunogenic CD8+ T-cell epitope derived from Î³-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia. Blood, 2006, 108, 2662-2668.	0.6	19
86	Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. Blood, 2006, 107, 1528-1536.	0.6	156
87	Efficient Presentation of Naturally Processed HLA Class I Peptides by Artificial Antigen-Presenting Cells for the Generation of Effective Antitumor Responses. Clinical Cancer Research, 2006, 12, 2967-2975.	3.2	38
88	Off the Shelf, GMP Grade Artificial APC Efficiently Generates Large Numbers of Antigen Specific CTLs Sufficient for the Treatment of Cancer and Infectious Disease.. Blood, 2004, 104, 3172-3172.	0.6	0
89	Highly Efficient Presentation of Endogenously Processed Class I Peptides by Artificial APC for the Generation of Effective Anti-Tumor Responses.. Blood, 2004, 104, 1355-1355.	0.6	0
90	Î³-Globin, a Tumor-Associated Antigen for Juvenile Myelomonocytic Leukemia (JMML): A Cell-Based Approach To Identify Tumor Antigenic Epitopes That Are Naturally Processed and Presented.. Blood, 2004, 104, 3418-3418.	0.6	0

#	Article	IF	Citations
91	Autoantibodies frequently detected in patients with aplastic anemia. Blood, 2003, 102, 4567-4575.	0.6	105
92	Reply to M.Z. Farooq et al. JCO Oncology Practice, 0, , .	1.4	0